EE200300419A - R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina - Google Patents
R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorinaInfo
- Publication number
- EE200300419A EE200300419A EEP200300419A EEP200300419A EE200300419A EE 200300419 A EE200300419 A EE 200300419A EE P200300419 A EEP200300419 A EE P200300419A EE P200300419 A EEP200300419 A EE P200300419A EE 200300419 A EE200300419 A EE 200300419A
- Authority
- EE
- Estonia
- Prior art keywords
- methyl
- aminopropane
- norepinephrine
- hydroxyphenyl
- oxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27373001P | 2001-03-06 | 2001-03-06 | |
| PCT/US2002/003385 WO2002070457A1 (en) | 2001-03-06 | 2002-02-20 | Inhibitor of monoamine uptake |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200300419A true EE200300419A (et) | 2004-02-16 |
Family
ID=23045157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300419A EE200300419A (et) | 2001-03-06 | 2002-02-20 | R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina |
Country Status (35)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT414238B (de) * | 2001-03-06 | 2006-10-15 | Lilly Co Eli | Neues hydroxyliertes 3-phenoxy-3-phenyl-1- aminopropan und dieses aminopropan enthaltende pharmazeutische formulierung |
| WO2005020976A2 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| KR20060121178A (ko) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제 |
| WO2011027359A2 (en) * | 2009-07-30 | 2011-03-10 | Matrix Laboratories Ltd | Novel process for the preparation of 4-hydroxy atomoxetine |
| WO2012020418A1 (en) | 2010-08-12 | 2012-02-16 | Matrix Laboratories Ltd | Novel polymorphs of 4-hydroxy atomoxetine hydrochloride |
| DE102013022397A1 (de) | 2013-12-19 | 2016-07-07 | Metrax Gmbh | Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage |
| GR1008819B (el) | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου |
| CN107935848B (zh) * | 2017-11-21 | 2020-12-22 | 中国农业科学院兰州畜牧与兽药研究所 | 一种六茜素衍生物及其制备方法和应用 |
| CA3117766A1 (en) * | 2018-10-31 | 2020-05-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| US4018895A (en) | 1974-01-10 | 1977-04-19 | Eli Lilly And Company | Aryloxyphenylpropylamines in treating depression |
| US4194009A (en) | 1974-01-10 | 1980-03-18 | Eli Lilly And Company | Aryloxyphenylpropylamines for obtaining a psychotropic effect |
| FR2432500A1 (fr) * | 1978-02-24 | 1980-02-29 | Roussel Uclaf | Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments |
| US5112619A (en) * | 1985-11-12 | 1992-05-12 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulation |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| ZA885824B (en) * | 1987-08-14 | 1989-04-26 | Merrell Dow Pharma | Novel antidepressants |
| ZA921292B (en) * | 1991-02-25 | 1993-08-23 | Lilly Co Eli | Treatment of lower urinary tract disorders. |
| TW514634B (en) | 1997-10-14 | 2002-12-21 | Lilly Co Eli | Process to make chiral compounds |
| WO2000058262A1 (en) | 1999-03-29 | 2000-10-05 | Eli Lilly And Company | Stereospecific method for preparing tomoxetine and intermediates thereof |
| AU3877500A (en) | 1999-04-09 | 2000-11-14 | Eli Lilly And Company | Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof |
| EP1395253A2 (en) * | 2000-11-15 | 2004-03-10 | Eli Lilly And Company | Treatment of anxiety disorders |
| AT414238B (de) * | 2001-03-06 | 2006-10-15 | Lilly Co Eli | Neues hydroxyliertes 3-phenoxy-3-phenyl-1- aminopropan und dieses aminopropan enthaltende pharmazeutische formulierung |
-
2002
- 2002-02-20 AT AT0904202A patent/AT414238B/de not_active IP Right Cessation
- 2002-02-20 IL IL15777902A patent/IL157779A0/xx unknown
- 2002-02-20 CA CA002440161A patent/CA2440161A1/en not_active Abandoned
- 2002-02-20 NZ NZ527431A patent/NZ527431A/en unknown
- 2002-02-20 CH CH01522/03A patent/CH695982A5/de not_active IP Right Cessation
- 2002-02-20 CZ CZ20032380A patent/CZ20032380A3/cs unknown
- 2002-02-20 ES ES02713538T patent/ES2305221T3/es not_active Expired - Lifetime
- 2002-02-20 HU HU0303341A patent/HUP0303341A3/hu unknown
- 2002-02-20 AP APAP/P/2003/002855A patent/AP2003002855A0/en unknown
- 2002-02-20 EE EEP200300419A patent/EE200300419A/xx unknown
- 2002-02-20 AU AU2002245385A patent/AU2002245385B2/en not_active Ceased
- 2002-02-20 KR KR10-2003-7011635A patent/KR20030092012A/ko not_active Ceased
- 2002-02-20 BR BR0207716-7A patent/BR0207716A/pt not_active IP Right Cessation
- 2002-02-20 EA EA200300978A patent/EA005768B1/ru not_active IP Right Cessation
- 2002-02-20 GB GB0323169A patent/GB2389851B/en not_active Expired - Fee Related
- 2002-02-20 LU LU91038A patent/LU91038B1/fr active
- 2002-02-20 SK SK1063-2003A patent/SK10632003A3/sk unknown
- 2002-02-20 TR TR2007/05146T patent/TR200705146T1/xx unknown
- 2002-02-20 US US10/468,553 patent/US20040082666A1/en not_active Abandoned
- 2002-02-20 CN CNB028060253A patent/CN1229331C/zh not_active Ceased
- 2002-02-20 WO PCT/US2002/003385 patent/WO2002070457A1/en not_active Ceased
- 2002-02-20 PL PL02363840A patent/PL363840A1/xx not_active Application Discontinuation
- 2002-02-20 HR HR20030710A patent/HRP20030710A2/hr not_active Application Discontinuation
- 2002-02-20 DE DE60226715T patent/DE60226715D1/de not_active Revoked
- 2002-02-20 FI FI20031191A patent/FI20031191A7/fi not_active IP Right Cessation
- 2002-02-20 JP JP2002569778A patent/JP2004525912A/ja not_active Ceased
- 2002-02-20 OA OA1200300215A patent/OA12494A/en unknown
- 2002-02-20 EP EP02713538A patent/EP1379492B1/en not_active Revoked
- 2002-02-20 AT AT02713538T patent/ATE396170T1/de not_active IP Right Cessation
- 2002-02-20 ES ES200350052A patent/ES2201942B2/es not_active Expired - Fee Related
-
2003
- 2003-08-11 LT LT2003075A patent/LT5143B/lt unknown
- 2003-09-02 EC EC2003004760A patent/ECSP034760A/es unknown
- 2003-09-03 SE SE0302361A patent/SE526598C2/sv not_active IP Right Cessation
- 2003-09-03 ZA ZA200306882A patent/ZA200306882B/en unknown
- 2003-09-04 DK DK200301267A patent/DK200301267A/da not_active Application Discontinuation
- 2003-09-04 NO NO20033921A patent/NO20033921L/no not_active Application Discontinuation
- 2003-09-10 LV LVP-03-100A patent/LV13119B/en unknown
-
2005
- 2005-05-09 US US11/125,348 patent/US7384983B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE05475B1 (et) | Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon | |
| ATE307571T1 (de) | Pharmazeutische formulierung enthaltend bicalutamid | |
| ATE334656T1 (de) | Flüssige pharmazeutische zusammensetzung | |
| NO20033384D0 (no) | Farmasöytisk formulering | |
| EE05378B1 (et) | LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks | |
| FI20011478L (fi) | Farmaseuttinen koostumus | |
| NO20025450L (no) | Ny farmasöytisk sammensetning | |
| DE60142197D1 (de) | Pharmazeutische Zusammensetzung | |
| ITTO20010008A0 (it) | Formulazione farmaceutica | |
| AT7729U3 (de) | Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat | |
| SI1407008T1 (sl) | Sestavek influenčne vakcine | |
| NO20035627D0 (no) | Farmasöytisk formulering | |
| NO20040254L (no) | Farmasoytiske sammensetninger som inneholder terbinafin og anvendelse derav | |
| FI20022128A0 (fi) | Farmaseuttinen koostumus | |
| DE60211183D1 (de) | Pharmazeutische zusammensetzung enthaltend lumiracoxib | |
| ATE350016T1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
| ATE366128T1 (de) | Pharmazeutische zusammensetzung | |
| NO20041485L (no) | Farmasoytisk formulering omfattende (R)-bicalutamid | |
| EE200200480A (et) | Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon | |
| DE10291905D2 (de) | Pharmazeutische Zusammensetzung | |
| ATE350029T1 (de) | Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain | |
| DE10107261B4 (de) | Pharmazeutische Zusammensetzung | |
| NO20041236L (no) | Farmasoytisk formulering | |
| SE0101171D0 (sv) | Pharmaceutical formulation | |
| SE0103565D0 (sv) | Pharmaceutical formulation |